SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-268185
Filing Date
2023-11-01
Accepted
2023-11-01 16:05:33
Documents
13
Period of Report
2023-11-01
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d527002d8k.htm   iXBRL 8-K 28223
2 EX-1.1 d527002dex11.htm EX-1.1 171545
  Complete submission text file 0001193125-23-268185.txt   371549

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atra-20231101.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20231101_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20231101_pre.xml EX-101.PRE 11264
7 EXTRACTED XBRL INSTANCE DOCUMENT d527002d8k_htm.xml XML 3370
Mailing Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320
Business Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320 805-623-4244
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 231368193
SIC: 2836 Biological Products, (No Diagnostic Substances)